Aspira Women's Health Inc.

Item 1.01 Entry into a Material Definitive Agreement. Explanatory Note On May 20, 2026, Aspira Women’s Health Inc. (“Aspira”) announced that it had entered into a Master Collaboration and License Agreement (the “Agreement”) with Cleveland Clinic Foundation (“CCF”), a non-profit educational, research and health care institution. The Agreement is effective as of May 20, 2026 (the “Effective Date”). Under the Agreement, Aspira and CCF will collaborate on biomedical research and development projects. Aspira shall pay to CCF a partnering fee in the aggregate amount of $125,000 (the " Partnering Fee"), payable as follows: (i) $50,000 within 30 days of the Effective Date; and (ii) $25,000 on each of the first, second, and third anniversaries of the Effective Date. The Partnering Fee is non-refundable and non-creditable against any other amounts payable under the Agreement or any Statement of Work, and is separate from, and in addition to, any compensation, cost reimbursement, milestones, or royalties payable under any Statement of Work. The initial term of the Agreement is five years from the Effective Date and may be extended upon mutual agreement. The Agreement may be terminated by either party (i) for any reason on at least sixty days’ prior written notice; (ii) in the event of a breach of this Agreement that is not cured within 30 days; or (iii) immediately upon written notice to Aspira if any part or all of this Agreement or a particular SOW is reasonably determined to jeopardize the overall tax-exempt status of CCF or any of its exempt Affiliates. The Agreement contains customary representations, covenants, and other provisions for arrangements of this type, including with respect to confidentiality, compliance with healthcare laws (including HIPAA), insurance, indemnification, non-exclusivity, and governing law. A copy of the Agreement is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and a copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description ──────────────────────────────────────────────────────────────────────────────────────────────── 10.1 Master Collaboration and License Agreement, dated as of May 20, 2026 99.1 Press Release issued by Aspira Women’s Health Inc. on May 26, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)